New drug shows promise for long-term immune deficiency treatment

NCT ID NCT05513586

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked the long-term safety of TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID). Participants received TAK-771 injections for up to 3 years. The main goal was to monitor side effects and immune reactions. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK-771 (immune globulin with hyaluronidase)
What this could lead to: If successful, this could confirm that TAK-771 is safe for long-term use in managing primary immunodeficiency diseases.
What could go wrong: This is a small, open-label extension study with only 15 participants, so results may not apply to all patients. Side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inborn error of immunity Primary Immunodeficiency Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNODEFICIENCY DISEASES (PID)

Contacts and locations

Locations

Gifu University Hospital

Gifu, Japan
Hiroshima University Hospital

Hiroshima, Japan
Hospital of University of Occupational and Environmental Health

Kitakyushu, Fukuoka, Japan
Kanagawa Children's Medical Center

Yokohama, Kanagawa, Japan
Kyushu University Hospital

Fukuoka, Japan
Nagoya University Hospital

Nagoya, Aichi-ken, Japan
Saitama Prefectual Children's Medical Center

Saitama, Japan
Shizuoka Childrens Hospital

Shizuoka, Japan
Tokyo Medical Dental University Hospital

Bunkyo-ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.